Mr. He served as patent examiner and re-examiner before joining Fairsky. He concluded examination of more than 700 invention patent applications, 200 utility model patent applications and 40 reexamination cases. One of the reexamination cases handled by him was awarded as one of the top ten cases of 2017 patent reexamination / invalidation. Mr. He has profound experiences in patent invalidation and infringement opinions, and participates in patent invalidation proceedings, patent administrative litigations and patent infringement litigations.
Social Title
Director of Working Committee of Intellectual Property Protection of WFCMS
·Advanced enterprise compliance engineer of China General Chamber of Commerce
Title Qualification
·Senior intellectual property professional
Social Position
·Member of the Intellectual Property Protection Working Committee under World Federation of Chinese Medicine Societies
·Senior corporate compliance officer of the China General Chamber of Commerce
·Member of the Intellectual Property Law Association of CLS
·Member of the Intellectual Property Business Research Committee of Beijing Chaoyang Lawyers Association
·External part-time lecturer of the School of Medicine and Pharmacy of Ocean University of China (September 2023 to August 2026)
·Member of the Intellectual Property Law Association of CLS
·Member of the Intellectual Property Business Research Committee of Beijing Chaoyang Lawyers Association
Professional Experience
1.Represented Haihe Pharmaceutical Co., Ltd., vs. Chugai Pharmaceutical Co., Ltd., in the first litigation case of pharmaceutical patent linkage regarding the medicament "Eldecalcitol Soft Capsules", the case being rated as one of "Top Ten Intellectual Property Cases in Chinese Courts in 2022" and selected as one of "2022 Top Ten Nominated Cases for Advancing the Process of Rule by Law in the New Era", etc.
2.Represented Humanwell Pharmaceutical Co., Ltd., vs. Purdue Pharma L.P., in the first administrative adjudication case of pharmaceutical patent linkage regarding the "Oxycodone Hydrochloride Sustained-release Tablet", with recognition of the technical solution of Humanwell Pharmaceutical Co., Ltd. not falling into the protection scope of the registered patent.
3. Represented Zhonghua Chemical et al., vs. Wanglong Group et al., in the case of know-how infringement regarding the "Vanillin", the case being rated as one of "Top Ten Cases in the People's Court in 2021" and selected as one of "Top Ten Intellectual Property Cases in Chinese Courts in 2021", etc.
4.Represented Yangtze River Pharmaceutical Group, vs. H LUNDBECK AS, in the case of patent infringement regarding the "Vortioxetine", forcing the opposite party to withdraw the lawsuit through non-infringement defense.
5.Represented JIANGSU LISIDE, vs. Clariant (Germany), in the set of cases of patent infringement/administrative adjudication regarding the "Aluminum Diethylphosphinate Flame Retardant", finally forcing the opposite party to withdraw the lawsuit/the request for administrative adjudication.
6.Represented Humanwell Pharmaceutical in the case of request for invalidation of the set of invention patents regarding the "Oxycodone Hydrochloride Sustained-release Tablet" held by Purdue Pharma L.P., successfully invalidating all patents involved.
7.Represented LISIDE in the case of request for invalidation of the set of invention patents regarding the "Aluminum Diethylphosphinate Flame Retardant" held by Clariant (Germany), successfully invalidating the whole or part of patents involved.
8.Represented Shanghai Cathay in response to the case of Shandong Guiyuan's request for invalidation of invention patent, successfully upholding the validity of the patent involved.
9.Represented IMEIK in response to the case of Sui's request for invalidation of invention patent, successfully upholding the validity of the patent involved.
10. Acted as intellectual property advisors in biopharmaceutical and chemical enterprises (e.g., CSPC Pharmaceutical, Sumitomo Pharmaceutical, SUZHOU EDDING, BEIJING COSCI, Viconepine, and JIANGSU LISIDE).
11.Performed technology transfer consulting services to biopharmaceutical and chemical entities (e.g., Jianchangbang Pharmaceutical, Jinyu Bio-TECHNOLOGY, Fuwai Hospital, SHENZHEN HERZ, Suzhou Healthy Tree, and JIANGSU LISIDE).
12.Organized a patentability search and analysis project covering FTO search and analysis of Class 1 small molecular COVID-19 drugs and patent applications relating thereto.
13.Organized a patentability search and analysis project covering FTO search and analysis of GIP and GLP-1 dual agonist peptide drugs and patent applications relating thereto.
14.Organized a project covering FTO search and analysis and subject search of strain+OMV protein multivalent combination meningococcal vaccines.
15.Organized a project covering FTO search and analysis of monoclonal antibody drug injector.
16.Organized a risk evaluation project for trade secrets in the BD process of hormone drug.
17.Organized a due diligence project on intellectual property rights for a certain LNP technology.
18.Acted as examiner for patent substantive examination, patent reexamination, PCT, and preliminary examination on utility model during service with CNIPA, holding qualification of acting as chairman of collegiate panel. Acted as chief examiner in the case rated as one of top ten cases of patent reexamination invalidation in 2017.
